Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
Astellas Pharma and US-based Vical announced on June 26 the initiation of a global PIII study of the cytomegalovirus vaccine ASP0113 for hematopoietic cell transplant recipients in the US. Europe and Japan will also be included later in the PIII…
To read the full story
Related Article
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
September 21, 2016
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Pfizer Brings Eisai into Nurtec Promotion in Japan
July 28, 2026
- Celltrion, Nippon Kayaku Broaden Alliance in Biopharma Biz
July 28, 2026
- Ishin Eyes Domestic Production of Allostem by August 2028
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…